—
C+
C+ The full Closelooknet — membership. Open the C+ overview

argenx NV ADR (ARGX) — chart, structure and Closelooknet read

The Closelooknet read

argenx develops antibody-based therapies for autoimmune disease and sells VYVGART for a rare neuromuscular disorder called generalised myasthenia gravis, plus a related formulation for immune thrombocytopenia and inflammatory nerve disease. Its pipeline includes further FcRn-targeted antibodies and candidates aimed at inflammation, IgA and other immune pathways, developed alone or through partners such as Zai Lab, Halozyme, OncoVerity and AbbVie.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ARGX, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelooknet

Where ARGX appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 47/100 · S&P 500 fund at 48, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-06
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 60th percentile of the window, -22.8% over 20 sessions. Factor regime → 2026-11-06
  • Sector × region Health care in US: −0.0% week · +9.9% month · +10.1% quarter · +27.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-07
  • Sovereign pressure Index -1.91 · down 2.45 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-06
How it trades on rate days beta 0.18 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How ARGX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.18 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), argenx NV ADR moved 0.18% on average · correlation 0.05 · higher than 14% of US names
  • Beta, last 3 months −0.27 less rate-sensitive lately than over the year
  • On the 10 worst bond days −0.75% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.73% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against ARGX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — argenx NV ADR

ARGX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
argenx develops antibody-based therapies for autoimmune disease and sells VYVGART for a rare neuromuscular disorder called generalised myasthenia gravis, plus a related formulation for immune thrombocytopenia and inflammatory nerve disease. Its pipeline includes further FcRn-targeted antibodies and candidates aimed at inflammation, IgA and other immune pathways, developed alone or through partners such as Zai Lab, Halozyme, OncoVerity and AbbVie. The company is based in Amsterdam and lists as an ADR in the United States.
Where it sits in the stack
argenx sits outside our AI build-out index; it belongs to the Healthcare sector of Closelooknet's universe, grouped with commercial-stage biopharma names rather than any stack layer.
Who it is priced against
Closelooknet's peer group places it with other scored US healthcare names, chosen for sharing sector and country rather than therapy area, including Regeneron, Vertex, BeiGene and Medpace; the market also names Alexion as a comparator in rare-disease antibody treatment.
Why Closelooknet tracks it
argenx carries a Closelooknet score built from three scored modules so far, with momentum reading strongest and valuation reading weakest. It holds no seat in our indices and has appeared once in the diary, in a Midday 10 note listing it among large-cap healthcare names hitting new highs.
What the diary watches
The diary watches whether further scored modules shift the balance between its strong momentum reading and its weaker valuation one as commercial data on VYVGART and pipeline readouts accumulate.

argenx NV ADR (ARGX) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 64/100 composite (momentum 77, quality 74, valuation 27) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 10 analyst actions on the wire · latest: price target by Stifel, 2026-10-22

The Street on this name

Analyst actions and the latest print for ARGX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Stifel — target 1,200 Target set to $1200 (+35.4% to spot) 2026-10-22
  • Price target Morgan Stanley — target 1,140 from 1,250 Target cut to $1140 from $1250 (+39.7% to spot) 2026-10-09
  • Price target Morgan Stanley — target 1,250 from 1,230 Target raised to $1250 from $1230 (+22.2% to spot) 2026-08-31

10 actions on the analyst wire since 2026-08-13: 1 downgrade, 9 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What ARGX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +1.3% in FY2025 248 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-07

Quick answers

What is argenx NV ADR (ARGX)?

argenx NV ADR trades as ARGX on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-07.

Is ARGX in a Closelooknet index?

Not currently — argenx NV ADR is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-07.

What is argenx NV ADR's Closelooknet composite score?

64 out of 100, with momentum 77, quality 74 and valuation 27 sub-scores, as of 2026-11-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ARGX trade against its moving averages?

argenx NV ADR trades 0.4% below its 50-day and 8.2% above its 200-day moving average (6.6% above its 20-day). As of 2026-11-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does argenx NV ADR compare with its peers?

Against its peer group (Biotechnology · US), argenx NV ADR (ARGX) sits 13.6% below its 52-week high, 0.4% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 22.7% below, Rigel Pharmaceuticals Inc (RIGL) is 24.6% below, Vertex Pharmaceuticals Inc (VRTX) is 4.6% below, as of 2026-11-06. Put any of them next to ARGX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does argenx NV ADR trade when bond yields rise?

Over the past year argenx NV ADR had a beta of 0.18 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 14% of US names. On the 10 sessions in which long bonds fell most it moved −0.75% on average, against −0.74% for the S&P 500. As of 2026-11-06; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about argenx NV ADR?

argenx NV ADR appears in 1 Closelooknet piece as of 2026-11-07, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelooknet said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does argenx NV ADR do?

argenx develops antibody-based therapies for autoimmune disease and sells VYVGART for a rare neuromuscular disorder called generalised myasthenia gravis, plus a related formulation for immune thrombocytopenia and inflammatory nerve disease. Its pipeline includes further FcRn-targeted antibodies and candidates aimed at inflammation, IgA and other immune pathways, developed alone or through partners such as Zai Lab, Halozyme, OncoVerity and AbbVie. The company is based in Amsterdam and lists as an ADR in the United States. Closelooknet's peer group places it with other scored US healthcare names, chosen for sharing sector and country rather than therapy area, including Regeneron, Vertex, BeiGene and Medpace; the market also names Alexion as a comparator in rare-disease antibody treatment. (Company snapshot of 2026-09-17.)

Where does argenx NV ADR sit in the AI build-out?

argenx sits outside our AI build-out index; it belongs to the Healthcare sector of Closelooknet's universe, grouped with commercial-stage biopharma names rather than any stack layer. argenx carries a Closelooknet score built from three scored modules so far, with momentum reading strongest and valuation reading weakest. It holds no seat in our indices and has appeared once in the diary, in a Midday 10 note listing it among large-cap healthcare names hitting new highs. (Company snapshot of 2026-09-17.)

Does argenx NV ADR pay a dividend?

No cash distribution shows in argenx NV ADR’s price series over the last three years. The share count rose 1.3% over the fiscal year. As of 2026-11-06; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on argenx NV ADR recently?

The most recent analyst action on argenx NV ADR on the Closelooknet wire is a price target by Stifel on 2026-10-22 (target 1,200). 10 actions on the analyst wire since 2026-08-13: 1 downgrade, 9 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ARGX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.